{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:19:23Z","timestamp":1783527563232,"version":"3.55.0"},"reference-count":50,"publisher":"Media Sphere Publishing Group","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. nevrol. psikhiatr. im. S.S. Korsakova"],"published-print":{"date-parts":[[2020]]},"DOI":"10.17116\/jnevro2020120081148","type":"journal-article","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T09:23:46Z","timestamp":1600161826000},"page":"148","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of the clinical benefits of second-line drugs modifying the course of multiple sclerosis"],"prefix":"10.17116","volume":"120","author":[{"given":"M.V.","family":"Zhuravleva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.V.","family":"Davydovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.V.","family":"Luchinina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.V.","family":"Shelekhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.O.","family":"Kurguzova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.Yu.","family":"Serebrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro2020120081148-1","unstructured":"Ulyanova OV, Kutashov VA. Comprehensive treatment of patients with multiple sclerosis in a multidisciplinary city hospital. Vestnik Kazakhskogo Natsionalnogo meditsinskogo universiteta. 2016;2:339-341. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120081148-2","doi-asserted-by":"publisher","DOI":"10.1186\/s40893-016-0016-9"},{"key":"key-10.17116\/jnevro2020120081148-3","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.039"},{"key":"key-10.17116\/jnevro2020120081148-4","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201911922107"},{"key":"key-10.17116\/jnevro2020120081148-5","doi-asserted-by":"publisher","DOI":"10.1111\/ane.12712"},{"key":"key-10.17116\/jnevro2020120081148-6","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s97956"},{"key":"key-10.17116\/jnevro2020120081148-7","unstructured":"European Medicines Agency. Ocrevus summary of product characteristics. 2019"},{"key":"key-10.17116\/jnevro2020120081148-8","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(09)70021-3"},{"key":"key-10.17116\/jnevro2020120081148-9","doi-asserted-by":"publisher","DOI":"10.2147\/dddt.s137572"},{"key":"key-10.17116\/jnevro2020120081148-10","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(11)70023-0"},{"key":"key-10.17116\/jnevro2020120081148-11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13819"},{"key":"key-10.17116\/jnevro2020120081148-12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"key-10.17116\/jnevro2020120081148-13","unstructured":"Instructions for the medical use of the drug Lemtrada (alemtuzumab). Sept 13, 2019. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120081148-14","unstructured":"Instructions for the medical use of the drug Ocrevus (ocrelizumab). Aug 01, 2018. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120081148-15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"key-10.17116\/jnevro2020120081148-16","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000158329.30470.D0"},{"key":"key-10.17116\/jnevro2020120081148-17","unstructured":"Instructions for medical use of the drug Tizabri (natalizumab). July 02, 2019. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120081148-18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"key-10.17116\/jnevro2020120081148-19","unstructured":"Tysabri SPC. Biogen Idec Ltd, Berkshire, UK. European Medicines Agency. [  WWW Document]. 2018. Accessed Feb 12, 2018.  https:\/\/www.medicines.org.uk\/emc\/product\/222"},{"key":"key-10.17116\/jnevro2020120081148-20","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327609.57688.ea"},{"key":"key-10.17116\/jnevro2020120081148-21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00451.x"},{"key":"key-10.17116\/jnevro2020120081148-22","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3324"},{"key":"key-10.17116\/jnevro2020120081148-23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31820d9596"},{"key":"key-10.17116\/jnevro2020120081148-24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907839"},{"key":"key-10.17116\/jnevro2020120081148-25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"key-10.17116\/jnevro2020120081148-26","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-018-9032-5"},{"key":"key-10.17116\/jnevro2020120081148-27","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0573-4"},{"key":"key-10.17116\/jnevro2020120081148-28","unstructured":"Instructions for the medical use of the drug Mavenclad (cladribine). (In Russ.)"},{"key":"key-10.17116\/jnevro2020120081148-29","doi-asserted-by":"publisher","DOI":"10.1185\/030079907x233142"},{"key":"key-10.17116\/jnevro2020120081148-30","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518771875"},{"key":"key-10.17116\/jnevro2020120081148-31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.11.021"},{"key":"key-10.17116\/jnevro2020120081148-32","unstructured":"Electronic database of international clinical trials. Accessed Feb 20, 2020. (In Russ.) https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03961204?term=ClassicMS&draw=2&rank=1"},{"key":"key-10.17116\/jnevro2020120081148-33","unstructured":"Lemtrada PI. Genzyme Corporation, MA, USA. Food and Drug Administration; 2018"},{"key":"key-10.17116\/jnevro2020120081148-34","unstructured":"FDA Safety Announcement. Drug safety and availability \u2014 FDA warns about rare but serious risks of stroke and blood vessel wall tears with multiple sclerosis drug lemtrada (alemtuzumab) [  WWW Document]. 2018. Accessed Jan 10, 2019.  https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm624247.htm"},{"key":"key-10.17116\/jnevro2020120081148-35","unstructured":"Safety announcement of the Food and Drug Administration. FDA Safety Announcement 2018. Date of the application: May 24, 2019. (In Russ.) https:\/\/www.fda.gov\/media\/118875\/download"},{"key":"key-10.17116\/jnevro2020120081148-36","unstructured":"EMA Press Release 2019. Accessed May 24, 2019 https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing_en.pdf"},{"key":"key-10.17116\/jnevro2020120081148-37","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160714669"},{"key":"key-10.17116\/jnevro2020120081148-38","unstructured":"Ocrevus SPC. Roche Products Limited, Hertfordshire, UK. European Medicines Agency. [  WWW Document]. 2018. Accessed Feb 12, 2018.  https:\/\/www.medicines.org.uk\/emc\/product\/8898"},{"key":"key-10.17116\/jnevro2020120081148-39","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0557-4"},{"key":"key-10.17116\/jnevro2020120081148-40","unstructured":"Press-release NeuroSens Oct 30, 2019. Date of the application: Mar 04, 2020.  https:\/\/neuro-sens.com\/pml-reported-in-patient-newly-treated-with-ocrelizumab"},{"key":"key-10.17116\/jnevro2020120081148-41","doi-asserted-by":"publisher","DOI":"10.1177\/1756285617716002"},{"key":"key-10.17116\/jnevro2020120081148-42","doi-asserted-by":"publisher","DOI":"10.1111\/cen3.12440"},{"key":"key-10.17116\/jnevro2020120081148-43","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04262.x"},{"key":"key-10.17116\/jnevro2020120081148-44","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/389360"},{"key":"key-10.17116\/jnevro2020120081148-45","unstructured":"Gilenya SPC. Novartis pharmaceuticals UK Ltd, Surrey, UK. European Medicines Agency. [  WWW Document]. 2018. Accessed Feb 12, 2018.  https:\/\/www.medicines.org.uk\/emc\/product\/4545"},{"key":"key-10.17116\/jnevro2020120081148-46","unstructured":"Instructions for medical use of the drug Guilenia (fingolimod). Oct 09, 2018. (In Russ.)"},{"key":"key-10.17116\/jnevro2020120081148-47","doi-asserted-by":"publisher","DOI":"10.1177\/2042098613481023"},{"key":"key-10.17116\/jnevro2020120081148-48","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005529"},{"key":"key-10.17116\/jnevro2020120081148-49","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12195"},{"key":"key-10.17116\/jnevro2020120081148-50","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"}],"container-title":["Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T09:29:29Z","timestamp":1600162169000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2020\/8\/1199772982020081148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"alternative-id":["10.17116\/jnevro2020120081148"],"URL":"https:\/\/doi.org\/10.17116\/jnevro2020120081148","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}